JPRN-UMIN000009483已完成2 期
Phase II study of cetuximab plus 5-FU/LV for unresectable colorectal cancer - Phase II study of cetuximab plus 5-FU/LV for unresectable colorectal cancer
Aichi Cancer Center Hospital0 个研究点目标入组 24 人开始时间: 2012年12月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Symptomatic brain metastasis Sever wattery diarrhea Paralytic or mechanical bowel obstruction Confirmed or suspected infection Severe pulmonary disease Severe comorbidity Pregnant or possibly pregnant, and nursing women Sever neurologic disease Receiving atazanavir sulfate Past history of monoclonal antibody sever allergy Past history of 5-FU/LV sever allergy Past history of treatment with Anti-EGFR Other conditions not suitable for this study
研究者
相似试验
已完成
2 期
Phase II study of biweekly cetuximab therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011361Department of Surgical Oncology Osaka City University10
进行中（未招募）
不适用
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
不适用
Phase II trial of Cetuximab in combination with chemotherapy (Carboplatinum and Navelbine) for patients with platinum-resistant head- and neckcancer - CCV-NKPlatinum-resistant head and neck cancerMedDRA version: 12.0Level: LLTClassification code 10067821Term: Head and neck cancerEUCTR2009-013878-40-DKOdense University Hospital
已完成
2 期
Phase II clinical trial of Cetuximab with Fluorouracil therapy for patients refractory or intolerable to Oxaliplatin and Irinotecan with KRAS wild-type unresectable/recurrent colorectal cancercolorectal cancerJPRN-UMIN000008377Department of Gastroenterological Surgery Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences45
已完成
不适用
Phase II sudy of cetuximab for the treatment of refractory or relapsed multiple myeloma Erbitux for Multiple MyelomACancerISRCTN81968533niversity of Cologne (Germany)33